← Back to Search

Molecular and Structural Imaging for Alzheimer's Disease

N/A

Recruiting

Led By Jennifer Whitwell, Ph.D.

Research Sponsored by Mayo Clinic

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

All subjects with Logopenic Aphasia (LPA) must present with early and dominant impairments in language

All subjects must have insidious onset, report progression of their symptoms, and meet current clinical diagnostic criteria for typical amnestic AD or an atypical AD syndrome such as Logopenic Aphasia (LPA) or Posterior Cortical Atrophy (PCA)

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 5 years

Awards & highlights

Study Summary

This trial looks at amyloid and tau in the brains of people with atypical Alzheimer's to see how it changes over time.

Who is the study for?

This study is for adults over 21 with Atypical Alzheimer's Disease, specifically those diagnosed with Logopenic Aphasia or Posterior Cortical Atrophy. Participants must have a person to report on their functioning and speak English as their primary language. They can't join if they've had strokes, tumors, severe memory issues early on, other neurodegenerative diseases, very poor vision, are pregnant/breastfeeding, or have MRI contraindications.Check my eligibility

What is being tested?

The trial is using advanced brain imaging techniques (F-18 AV 1451 and C-11 PiB) to investigate the presence of amyloid and tau proteins in patients' brains. It aims to see how these protein levels change over one year in individuals with atypical forms of Alzheimer's disease.See study design

What are the potential side effects?

While the document doesn’t specify side effects related to F-18 AV 1451 and C-11 PiB imaging agents used in PET scans directly, common side effects from such procedures may include discomfort at injection site or allergic reactions; however individual experiences may vary.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I have trouble finding the right words and forming sentences.

Select...

I have Alzheimer's with worsening memory loss or specific symptoms like LPA or PCA.

Select...

I am over 21 years old.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 5 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~5 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and 5 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Amount of Amyloid protein in the brain of patients with Logopenic Aphasia (LPA) or Posterior Cortical Atrophy (PCA).

Amount of Tau protein in the brain of patients with Logopenic Aphasia (LPA) or Posterior Cortical Atrophy (PCA).

Secondary outcome measures

Rates of change in amyloid-PET burden over time.

Rates of change in tau-PET burden over time.

Trial Design

2Treatment groups

Experimental Treatment

Group I: Tau PET Scan, F-18 AV 1451Experimental Treatment2 Interventions

All subjects will receive two Tau PET scans during this study.

Group II: PiB PET Scan, C-11 PiBExperimental Treatment2 Interventions

All subjects will receive two PiB PET scans during this study.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

C-11 PiB

2010

Completed Phase 1

~240

0 / 3Eligibility criteria met

Find a Location

Who is running the clinical trial?

Mayo ClinicLead Sponsor

3,221 Previous Clinical Trials

3,767,892 Total Patients Enrolled

National Institute on Aging (NIA)NIH

1,676 Previous Clinical Trials

28,021,439 Total Patients Enrolled

Jennifer Whitwell, Ph.D.Principal Investigator - Mayo Clinic

Mayo Clinic

Media Library

C-11 PiB Clinical Trial Eligibility Overview. Trial Name: NCT02740634 — N/A

Mild Cognitive Impairment Research Study Groups: Tau PET Scan, F-18 AV 1451, PiB PET Scan, C-11 PiB

Mild Cognitive Impairment Clinical Trial 2023: C-11 PiB Highlights & Side Effects. Trial Name: NCT02740634 — N/A

C-11 PiB 2023 Treatment Timeline for Medical Study. Trial Name: NCT02740634 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What prior experiments have featured C-11 PiB as a focus?

"Presently, there are four ongoing clinical trials researching C-11 PiB and no research in Phase 3. Primarily located in Nashville, Tennessee, these studies have five distinct enrolment sites."

Answered by AI

What is the maximum participant capacity for this experiment?

"Affirmative. Clinicaltrials.gov has information that this research is currently accepting participants, having been initially listed on May 1st 2016 and revised most recently in April 5th 2022. The team behind the project hopes to enrol 60 individuals between one site of investigation."

Answered by AI

Are new participants being enrolled in this clinical investigation currently?

"Affirmative. Clinicaltrials.gov has indicated that this clinical trial, which was first published on May 1st 2016, is actively searching for participants. Sixty individuals are set to be recruited from a single medical centre."

Answered by AI

Who qualifies to join this experiment?

"The requirements for eligibility are aphasia and an age between 21 and 80. This particular medical research is seeking to enroll 60 participants in total."

Answered by AI

Do individuals above the age of 30 meet the qualifications for this research project?

"The prerequisites for inclusion in this clinical trial include being between 21 to 80 years of age. For younger and older patients, there are 70 trials available with a lower bound age limit of 18 and 758 trials with an upper bound cap at 65+."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Molecular and Structural Imaging in Alzheimer's Disease: A Longitudinal Study

Jennifer Whitwell 2016. "Molecular and Structural Imaging in Alzheimer's Disease: A Longitudinal Study". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT02740634.

All > Aphasia > Primary Progressive Aphasia